FibroGen downgraded by BofA Securities

6/26/23 1:16:35 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

BofA Securities downgraded FibroGen from Buy to Neutral

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FGEN

Date	Price Target	Rating	Analyst
8/8/2023	$4.00 → $2.00	Neutral → Underperform	BofA Securities
6/26/2023		Buy → Hold	Stifel
6/26/2023		Buy → Neutral	BofA Securities
6/26/2023		Outperform → Mkt Perform	Raymond James
6/26/2023		Outperform → Mkt Perform	William Blair
6/2/2023	$23.00 → $32.00	Hold → Buy	Stifel
1/31/2023		Mkt Perform → Outperform	William Blair
1/26/2023	$35.00	Mkt Perform → Outperform	Raymond James